Skip to main content
SpringerLink
Log in

Anxiolytics, Sedatives, and Miscellaneous Drugs

  • Chapter
Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents

Abstract

This chapter contains discussions of anxiolytics and sedatives and several miscellaneous drugs that do not fit naturally into the remaining drug chapters. Included here are reviews of central nervous system (CNS) depressants (such as the benzodiazepines), antihistamines and anticholinergics, and atypical anxiolytics. Under the rubric of “miscellaneous drugs,” we have included Clonidine and guanfacine, melatonin, hypericin, tryptophan and 5-hydroxytryptophan, fenfluramine, the ß-blockers, and the opiate antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association: Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report. Washington, DC, American Psychiatric Press, 1990.

    Google Scholar 

  2. Gilman AG, Rall TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990.

    Google Scholar 

  3. Gelenberg AJ, Bassuk EL, Schoonover SC (eds): The Practitioner’s Guide to Psychoactive Drugs, ed 3. New York, Plenum Press, 1991.

    Google Scholar 

  4. Greenblatt DJ, Shader, RI: Benzodiazepines in Clinical Practice. New York, Raven Press, 1974.

    Google Scholar 

  5. Baldessarini RJ: Drugs and the treatment of psychiatric disorders, in Gilman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 383–435.

    Google Scholar 

  6. Kennedy SK, Longnecker DE: History and principles of anesthesiology, in Gilman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 269–284.

    Google Scholar 

  7. Kutcher SP, Reiter S, Gardner DM, et al: The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 15:41–68, 1992.

    PubMed  Google Scholar 

  8. Rail TW: Hypnotics and sedatives; ethanol, in Gilman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 345–382.

    Google Scholar 

  9. Coffey BJ: Anxiolytics for children and adolescents: Traditional and new drugs. J Child Adolesc Psycho-pharmacol 1:57–86, 1990.

    Google Scholar 

  10. Klein DF, Mannuzza S, Chapman T, et al: Child panic revisited. J Am Acad Child Adolesc Psychiatry 31:112 – 116, 1992.

    PubMed  Google Scholar 

  11. Bernstein GA, Borchardt CM: Anxiety disorders of childhood and adolescence: A critical review. J Am Acad Child Adolesc Psychiatry 30:519–532, 1991.

    PubMed  Google Scholar 

  12. Allen AJ, Leonard H, Swedo SE: Current knowledge of medications for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 34:976–986, 1995.

    PubMed  Google Scholar 

  13. Bernstein GA, Perwien AR: Anxiety disorders, in Riddle MA (ed): Pediatric psychopharmacology. Child Adolesc Clin North Am 4:305–322, 1995.

    Google Scholar 

  14. Popper DW: Psychopharmacological treatment of anxiety disorders in adolescents and children. J Clin Psychiatry 54(suppl):52–63, 1993.

    PubMed  Google Scholar 

  15. Roy-Byrne PP, Wingerson D: Pharmacotherapy of anxiety disorders, in Tasman A, Riba MB (eds): American Psychiatric Press Review of Psychiatry. Washington, DC, American Psychiatric Press, 1992, vol 11, pp 260–284.

    Google Scholar 

  16. Simeon JG, Ferguson HB, Knott V, et al: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 31:29–33, 1992.

    PubMed  Google Scholar 

  17. Aman MG, Werry JS: Methylphenidate and diazepam in severe reading retardation. J Am Acad Child Psychiatry 21:31–37, 1982.

    PubMed  Google Scholar 

  18. Graae F, Milner J, Rizzotto L. et al: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:372–376, 1994.

    PubMed  Google Scholar 

  19. Werry JS: Overanxious disorder: A review of its taxonomic properties. J Am Acad Child Adolesc Psychiatry 30:533–544, 1991.

    PubMed  Google Scholar 

  20. Brown TA, Hertz RM, Barlow DH: New developments in cognitive-behavioral treatment of anxiety disorders, in Tasman A, Riba MB (eds): American Psychiatric Press Review of Psychiatry. Washington, DC, American Psychiatric Press, 1992, vol 11, pp 285–306.

    Google Scholar 

  21. Werry JS, Wollersheim JP: Behavior therapy with children and adolescents: A twenty year overview. J Am Acad Child Adolesc Psychiatry 28:1–18, 1989.

    PubMed  Google Scholar 

  22. Richman N, Douglas J, Hunt H, et al: Behavioural methods in the treatment of sleep disorders: A pilot study. J Child Psychol Psychiatry 26:581–590, 1985.

    PubMed  Google Scholar 

  23. Home J: Sleep and its disorders in children. J Child Psychol Psychiatry 33:473–487, 1992.

    Google Scholar 

  24. Dahl RE: The pharmacologic treatment of sleep disorders. Psychiatr Clin North Am 15:161–178, 1992.

    PubMed  Google Scholar 

  25. Dahl RE: Child and adolescent sleep disorders, in Riddle MA (ed): Pediatric psychopharmacology. Child Adolesc Clin North Am 4:323–341, 1995.

    Google Scholar 

  26. McClellan JM, Werry JS: Schizophrenia. Psychiatr Clin North Am 15:131–148, 1992.

    PubMed  Google Scholar 

  27. Campbell M, Gonzalez NM, Silva RR: The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 15:69–85, 1992.

    PubMed  Google Scholar 

  28. Steingard RJ, Goldberg M, Lee D, et al: Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 33:394–399, 1994.

    PubMed  Google Scholar 

  29. Wilens T, Spencer T, Biederman J, et al: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34:110–112, 1995.

    PubMed  Google Scholar 

  30. Ciraulo DA, Shader RI, Greenblatt DJ, et al: Drug Interactions in Psychiatry. Baltimore: Williams & Wil-kins, 1989.

    Google Scholar 

  31. Werry JS, Carlielle J: The nuclear family, suburban neurosis, and iatrogenesis in Auckland mothers of young children. J Am Acad Child Psychiatry 22:172–179, 1982.

    Google Scholar 

  32. Garrison JC: Histamine, bradykinin, 5-hydroxytryptamine and their antagonists, in Gilman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilmans The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 575–599.

    Google Scholar 

  33. Werry JS: Anticholinergic sedatives, in Burrows GD, Werry JS (eds): Advances in Human Psychopharmacology. Greenwich, Conn, JAI Press, 1980, pp 19–42.

    Google Scholar 

  34. Richman N: A double-blind drug trial of treatment in young children with waking problems. J Child Psychol Psychiatry 26:591–598, 1985.

    PubMed  Google Scholar 

  35. Simeon J, Knott VJ, DuBois C, et al: Buspirone therapy of mixed anxiety disorders in childhood and adolescence: A pilot study. J Child Adolesc Psychopharmacol 4:159–170, 1994.

    Google Scholar 

  36. Gross MD: Buspirone in ADHD with ODD [letter]. J Am Acad Adolesc Psychiatry 34:1260, 1995.

    Google Scholar 

  37. Mandoki M: Buspirone treatment of truamatic brain injury in a child who is highly sensitive to adverse effects of psychotropic medications. J Child Adolesc Psychopharmacol 4:129–139, 1994.

    Google Scholar 

  38. Soni P, Weintraub AL: Buspirone associated mental changes. J Am Acad Adolesc Psychiatry 31:1098–1099, 1992.

    Google Scholar 

  39. Realmuto GL, August GJ, Garfinkel BD: Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9:122–125, 1989.

    PubMed  Google Scholar 

  40. Zwier KJ, Rao U: Buspirone use in an adolescent with social phobia and mixed personality disorder (Cluster A type). J Am Acad Adolesc Psychiatry 33:1007–1011, 1994.

    Google Scholar 

  41. Gelenberg AJ, Bassuk EL, Schoonover SC: Practitioners Guide to Psychoactive Drugs ed 3. New York, Plenum, 1991, pp 199–200.

    Google Scholar 

  42. Hunt RD, Capper L, O’Connell P: Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1:87–102, 1990.

    PubMed  Google Scholar 

  43. Horrigan JP, Barnhill LJ: Guanfacine for treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 5:215–223, 1995.

    Google Scholar 

  44. Gerber JG, Nies AS: Antihypertensive agents and the drug treatment of hypertension, in Gilman AG, Rail TW, Nies AS, Taylor P (eds): Goodman and Gilmans The Pharmacological Basis of Therapeutics\ ed 8. New York, Pergamon Press, 1990.

    Google Scholar 

  45. Cohen DJ, Riddle MA, Leckman JF: Pharmacotherapy of Tourette’s syndrome and associated disorders. Psychiatr Clin North Am 15:109–130, 1992.

    PubMed  Google Scholar 

  46. Chappie PB, Leckman JF, Riddle MA et al: The pharmacological treatment of tic disorders, in Riddle MA (ed): Pediatric psychopharmacology. Child Adolesc Clin North Am 4:197–216, 1995.

    Google Scholar 

  47. Horacek HJ: Clonidine extended-release capsules as an alternative to oral tablets and transdermal patches. J Child Adolesc Psychopharmacol 4:211–212, 1994.

    Google Scholar 

  48. Lowenthal DT, Matzek KM, MacGregor TR: Clinical pharmacokinetics of Clonidine. Clin Pharmacokinet 14:287–310, 1988.

    PubMed  Google Scholar 

  49. Hunt RD, Arnsten A, Asbell MD: An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder in boys. J Am Acad Child Adolesc Psychiatry 34:50–54, 1995.

    PubMed  Google Scholar 

  50. Swanson JM, Flockhart D, Udrea D, et al: Clonidine in the treatment of ADHD: Questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301–304, 1995.

    Google Scholar 

  51. Swanson JM, Udrea D, Cantwell D, et al: Clonidine in the treatment of children with ADHD I: Efficacy. Personal communication, 1995.

    Google Scholar 

  52. Hunt RD, Minderaa RB, Cohen DJ: Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24:617–629, 1985.

    PubMed  Google Scholar 

  53. Singer HS, Brown J, Quaskey S, et al: The treatment of attention deficit hyperactivity disorder in Tourette’s Syndrome: A double blind placebo-controlled study with Clonidine and desipramine. Pediatrics 95:74–81, 1995.

    PubMed  Google Scholar 

  54. Jaselskis CA, Cook EH, Fletcher KE, et al: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327, 1992.

    PubMed  Google Scholar 

  55. Fankhauser MP, Karumanchi VC, German ML, et al: A double-blind, placebo-controlled study of the efficacy of transdermal Clonidine in autism. J Clin Psychiatry 53:77–82, 1992.

    PubMed  Google Scholar 

  56. Ghaziuddin M, Tsai L, Ghaziuddin N: Clonidine for autism [letter to the editor]. J Child Adolesc Psychopharmacol 2, 1992.

    Google Scholar 

  57. Prince JB, Wilens TE, Biederman J, et al: Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder: A systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 35:599–605, 1996.

    PubMed  Google Scholar 

  58. Wilens T, Biederman J, Spencer T: Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 33:424–426, 1994.

    PubMed  Google Scholar 

  59. Kemph JP, Devane CL, Levin GM, et al: Treatment of aggressive children with Clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577–581, 1993.

    PubMed  Google Scholar 

  60. Schvehla TJ, Mandoki MW, Sumner GS: Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct. South Med J 87:692–695, 1994.

    PubMed  Google Scholar 

  61. Stowe JK, Kreusi MJP, Lelio DF: Psychopharmacology of aggressive states and features of conduct disorder, in Riddle MA (ed): Pediatric psychopharmacology. Child Adolesc Clin North Am 4:359–380, 1995.

    Google Scholar 

  62. Althaus M, Vink HJ, Minderaa, RR et al: Lack of effect of Clonidine on stuttering in children. Am J Psychiatry 152:1087–1089, 1995.

    PubMed  Google Scholar 

  63. Swanson JM, Udrea D, Cantwell D, et al: Clonidine in the treatment of children with ADHD II: Side effects. Personal communication, 1995.

    Google Scholar 

  64. Levin GM, Burton-Teston K, Murphy T: Development of precocious puberty in two children treated with Clonidine for aggressive behavior. J Child Adolesc Psychopharmacol 3:127–131, 1993.

    PubMed  Google Scholar 

  65. Hoffman BB, Lefkowitz RJ: Catehcolamines and sympthomimetic drugs, in Gilman AG, Rail TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990.

    Google Scholar 

  66. Chandran KSK: ECG and Clonidine. J Am Acad Child Adolesc Psychiatry 33:1351–1352, 1994.

    PubMed  Google Scholar 

  67. Dawson PM, Zanden JAV, Werkman SW, et al: Cardiac dysrhythmia with use of Clonidine in explosive disorder. DICP, The Annals of Pharmacotherapy 23:465, 1989.

    Google Scholar 

  68. Popper CW: Combining methylphenidate and Clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 5:157–167, 1995.

    Google Scholar 

  69. Wilens T, Biederman J: Safety of Clonidine and nortriptyline [letter]. J Am Acad Child Adolesc Psychiatry 33:142–143, 1994.

    Google Scholar 

  70. Geller DA, Biederman J, Reed ED, et al: Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36–44,1995.

    PubMed  Google Scholar 

  71. Fenichel RR: Combining methylphenidate and Clonidine: The role of post-marketing surveillance. J Child Adolesc Psychopharmacol 5:155–156, 1995.

    Google Scholar 

  72. Henretig FM: Special considerations in the poisoned pediatric population. Emerg Med Clin North Am 12:549–567, 1994.

    PubMed  Google Scholar 

  73. Wiley JF, Wiley CC, Torrey SB, et al: Clonidine poisoning in young children. J Pediatr 116:654–658,1990.

    PubMed  Google Scholar 

  74. Cavallo A: The pineal gland in human beings: Relevance to pediatrics. J Pediatr 123:844–851, 1993.

    Google Scholar 

  75. Webb SM, Puig-Domingo M: Role of melatonin in health and disease. Clin Endocrinol 42:221–234, 1995.

    Google Scholar 

  76. Reiter RJ: The pineal gland and melatonin in relation to aging: A summary of theories and of the data. Exp Gerontol 30:199–212, 1995.

    PubMed  Google Scholar 

  77. Masters KJ: Melatonin for sleep problems [letter]. J Am Acad Child Adolesc Psychiatry 35:704, 1996.

    PubMed  Google Scholar 

  78. Regestein QR, Pavlova M: Treatment of delayed sleep phase syndrome. Gen Hosp Psychiatry 17:335–345, 1995.

    PubMed  Google Scholar 

  79. Palm L, Bleenow G, Wetterberg: Correction of a non-24-hour sleep/wake cycle by melatonin in a blind retarded boy. Ann Neurol 29:336–339, 1991.

    PubMed  Google Scholar 

  80. Jan JE, Espezel H, Appleton RE: The treatment of sleep disorders with melatonin. Dev Med Child Neurol 36:97–107, 1994.

    PubMed  Google Scholar 

  81. Kennedy SH: Melatonin disturbances in anorexia nervosa and bulimia. Int J Eat Dis 16:257–265, 1994.

    Google Scholar 

  82. DeSmet PA, Nolen WA: St. John’s wort as an antidepressant [editorial]. Br Med J 313:241–245, 1996.

    Google Scholar 

  83. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D: St John’s wort for depression— an overview and meta-analysis of randomised clinical trials. Br Med J 313:253–258, 1996.

    Google Scholar 

  84. Sokol MS, Campbell M: Novel psychotropic agents in the treatment of developmental disorders, in Aman MG, Singh NN (eds): Psychopharmacology of the Developmental Disorders. Berlin, Springer-Verlag, 1988, pp 146–167.

    Google Scholar 

  85. Goodwin FK, Jamison KR: Manie-Depressive Illness. London, Oxford University Press, 1990, pp 622–653.

    Google Scholar 

  86. Pinder RM, Brogden RN, Sawyer PR, et al: Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10:241–328, 1975.

    PubMed  Google Scholar 

  87. Aman MG, Kern RA: Review of fenfluramine in the treatment of the developmental disabilities. J Am Acad Child Adolesc Psychiatry 28:549–565, 1989.

    PubMed  Google Scholar 

  88. Campbell M: Annotation: Fenfluramine treatment of autism. J Child Psychol Psychiatry 29:1–10, 1988.

    PubMed  Google Scholar 

  89. Du Verglas G, Banks SR, Guyer KE: Clinical effects of fenfluramine on children with autism: A review of the research. J Autism Dev Disord 18:297–308, 1988.

    PubMed  Google Scholar 

  90. Gillberg C, Aman MG, Reiss A: Fenfluramine, in Reiss S, Aman MG (eds.): Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio, The Nisonger Center UAP, 1998.

    Google Scholar 

  91. Geller E, Ritvo ER, Freeman BJ, et al: Preliminary observation on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307:165–169, 1982.

    PubMed  Google Scholar 

  92. Donnelly M, Rapoport JL, Potter WZ, et al: Fenfluramine and dextroamphetamine treatment of childhood hyperactivity: Clinical and biochemical findings. Arch Gen Psychiatry 46:205–212, 1989.

    PubMed  Google Scholar 

  93. Selikowitz M, Sunman J, Pendergast A, et al: Fenfluramine in Prader—Willi syndrome: A double blind, placebo controlled trial. Arch Dis Child 65:112–114, 1990.

    PubMed  Google Scholar 

  94. Aman MG, Kern RA, McGhee, et al: Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. J Am Acad Child Adolesc Psychiatry 32:851–859, 1993.

    PubMed  Google Scholar 

  95. Aman MG, Kern RA, Osborne P, et al: Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects. Am J Ment Retard 101:521–534, 1997.

    PubMed  Google Scholar 

  96. Aman MG, Kern RA, Osborne P, et al: Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Cognitive effects. Unpublished manuscript, Ohio State University, 1998.

    Google Scholar 

  97. Connolly HM, Crary JL, McGoon MD, et al: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588, 1997.

    PubMed  Google Scholar 

  98. Graham DJ, Green L: Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:635, 1997.

    PubMed  Google Scholar 

  99. Cannistra LB, Davis SM, Bauman AG: Valvular disease associated with dexfenfluramine. N Engl J Med 337:636., 1997.

    PubMed  Google Scholar 

  100. FDA analysis of cardiac valvular dysfunction with use of appetite suppressants, http://www.fda.gov/cder/news/slide/index.htm.

  101. Johannes L, Langreth R: Diet drugs’ side effects are still a mystery. The Wall Street Journal, September 18, 1997, pp. Bl, B5.

    Google Scholar 

  102. Harvey JA, McMaster SE: Fenfluramine: Evidence for a neurotoxic action on midbrain and a long-term depletion of serotonin. Psychopharmacol Commun 1:217–228, 1975.

    PubMed  Google Scholar 

  103. Schuster CR, Lewis M, Seiden LS: Fenfluramine: Neurotoxicity. Psychopharmacol Bull 22:148–151, 1986.

    PubMed  Google Scholar 

  104. Physicians’ Desk Reference, ed 46. Oradell, NJ, Medical Economics Co, 1992.

    Google Scholar 

  105. Arnold LE, Aman MG: Beta blockers in mental retardation and developmental disorders. J Child Adolesc Psychopharmacol 1:361–373, 1991.

    PubMed  Google Scholar 

  106. Fraser WI, Ruedrich S, Kerr, M et al: Beta-adrenergic blockers, in Reiss S, Aman MG (eds): Psychoactive Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio, The Nisonger Center UAP, 1998.

    Google Scholar 

  107. Neppe VM: Innovative Psychopharmacotherapy. New York, Raven Press, 1989.

    Google Scholar 

  108. Hoffman BB, Lefkowitz, RJ: Adrenergic receptor antagonists, in Gilman AG, Rall TW, Nies AS, et al (eds): Goodman and Gilmans The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 221–243.

    Google Scholar 

  109. Holroyd KA, France JL, Cordingley GE, et al: Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. J Consult Clin Psychol 2:327–330, 1995.

    Google Scholar 

  110. Holroyd KA, Penzien DB, Cordingley G: Propranolol in the management of recurrent migraine: A meta-analytic review. Headache 31:333–340, 1991.

    PubMed  Google Scholar 

  111. Coffey BJ: Anxiolytics for children and adolescents. Traditional and new drugs. J Child Adolesc Psychopharmacol 1:57–83, 1990.

    PubMed  Google Scholar 

  112. Kuperman S, Stewart MA: Use of propranolol to decrease aggressive outbursts in younger patients. Psychosomatics 28:315–319, 1987.

    PubMed  Google Scholar 

  113. Connor DF: Nadolol for self-injury, overactivity, inattention, and aggression in a child with pervasive developmental disorder. J Child Adolesc Psychopharmacol 4:101–111, 1994.

    Google Scholar 

  114. Lang C, Remington D: Case study: Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent. J Am Acad Child Adolesc Psychiatry 33:265–269.

    Google Scholar 

  115. Schmidt JG, Dombovy ML, Watkins K: Treatment of viral encephalitis organic personality disorder and autistic features with propranolol: A case report. J Neurol Rehab 9:45–45, 1995.

    Google Scholar 

  116. Hayes PE, Schultz SC: Beta-blockers in anxiety disorders. J Affect Dis 13:119–130, 1987.

    PubMed  Google Scholar 

  117. Famularo R, Kinscheroff R, Fenton T: Propranolol treatment for childhood post-traumatic stress disorder, acute type. Am J Dis Child 142:1244–1247, 1988.

    PubMed  Google Scholar 

  118. Jaffe JH, Martin WR: Opioid analgesics and antagonists, in Gilman AG, Rall TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 485–521.

    Google Scholar 

  119. Sandman CA, Datta PC, Barron J, et al: Naloxone attenuates self-abusive behavior in developmentally disabled clients. Appl Res Ment Retard 4:5–11, 1983.

    PubMed  Google Scholar 

  120. Sandman CA: The opiate hypothesis in autism and self-injury. J Child Adolesc Psychopharmacol 1:237 – 248, 1990/1991.

    Google Scholar 

  121. Aman MG: Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities. Ann Clin Psychiatry 5:171–188, 1993.

    PubMed  Google Scholar 

  122. Aman MG: Pharmacotherapy in the developmental disabilities: New developments. Aust N Z J Dev Disabil 17:183–199, 1991.

    Google Scholar 

  123. Sandman CA, Thompson T, Barrett R, et al: Opiate blockers, in Reiss S, Aman MG (eds): Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio, The Nisonger Center UAP, 1998.

    Google Scholar 

  124. Hetrick W, Taylor D, Touchette P, et al: Treatment of self-injurious behavior with naltrexone: Effects in SIB, learning, and neurological function. Paper presented at the Gatlinburg Conference on Research and Theory in Mental Retardation and Developmental Disabilities, Key Biscayne, Fla, 1991.

    Google Scholar 

  125. Thompson T, Hackenberg T, Cerutti D, et al: Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of medication effects. Am J Ment Retard 99:85–102, 1994.

    PubMed  Google Scholar 

  126. Sandman CA, Hetrick WP, Taylor DV, et al: Naltrexone reduces self-injury and improves learning. Exp Clin Psychopharmacol 1:1–17, 1993.

    Google Scholar 

  127. Campbell M, Anderson LT, Small AM, et al: Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32:1283–1291, 1993.

    PubMed  Google Scholar 

  128. Willemsen-Swinkles SH, Buitelaar JK, Nijhof GJ, et al: Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Arch Gen Psychiatry 52:766–773, 1995.

    Google Scholar 

  129. Deutsch SI: Rationales for the administration of opiate antagonists in treating infantile autism. Am J Ment Defic 90:631–635, 1986.

    PubMed  Google Scholar 

  130. Sahley TL, Panksepp J: Brain opioids and autism: An updated analysis of possible linkages. J Autism Dev Disabil 17:201–216, 1987.

    Google Scholar 

  131. Campbell M, Overall JE, Small AM, et al: Naltrexone in autistic children: An acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 28:200–206, 1989.

    PubMed  Google Scholar 

  132. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, et al: Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 58:203–215, 1995.

    PubMed  Google Scholar 

  133. Kolmen BD, Feldman HM, Handen BL, et al: Naltrexone in young autistic children: A double-blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 34:223–231, 1995.

    PubMed  Google Scholar 

  134. Herman BH, Asleson GS, Powell A, et al: Cardiovascular and other physical effects of acute administration of naltrexone in autistic children. J Child Adolesc Psychopharmacol 3:157–168, 1993.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Auckland, Auckland, New Zealand

    John Scott Werry M.D.

  2. The Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University, Columbus, Ohio, 43210-1296, USA

    Michael G. Aman Ph.D.

Authors
  1. John Scott Werry M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael G. Aman Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Emeritus Professor of Psychiatry, University of Auckland, Auckland, New Zealand

    John Scott Werry M.D.

  2. Psychology and Psychiatry, The Ohio State University, Columbus, Ohio, USA

    Michael G. Aman Ph.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Werry, J.S., Aman, M.G. (1999). Anxiolytics, Sedatives, and Miscellaneous Drugs. In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0086-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-0086-9_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-45885-9

  • Online ISBN: 978-1-4899-0086-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation